Back

Relationship between the presence of heart failure and other factors among patients with lipid disorders

11 May 2024 (15:51 - 17:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - prevention Prevention HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Bozena Sosnowska

Medical University of Lodz, Lodz (Poland)

6 More presentations in this session

Presentation thumbnail
Implementation of a heart failure management programme (HF-MP) to improve patient access to services throughout their heart failure journey: a service improvement evaluation.
Mr R. Williams (Bridgend, GB)
Abstract Slides Video
Presentation thumbnail
Transcatheter aortic valve implantation initial experience in high risk patients with heart failure
Professor H. Sisakian (Yerevan, AM)
Abstract Slides Video
Presentation thumbnail
Mathematical model for estimating readmissions during the vulnerable period of patients with heart failure
Assistant Professor A. Lacraru (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
The AST to ALT ratio: a new predictor for left ventricular systolic dysfunction following ST segment myocardial infarction
Assistant Professor V. Halatiu (Targu Mures, RO)
Abstract Slides Video
Presentation thumbnail
Efficacy of in-hosptal initiation of dapagliflozin in prevention of heart failure in non-diabetic patients with anterior wall ST-segment elevation acute myocardial infarction
Doctor L. Hayrapetyan (Yerevan, AM)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - prevention

The Event

Event poster

Heart Failure 2024

11 May 2024 15:51 CET
You may be interested in
thumbnail
Congress Presentation
Lipid risk profile in elderly patients with AHF and long-term follow-up
thumbnail
Congress Presentation
Lipid-lowering therapy is associated with lower mortality in heart failure patients: Insights from Swedish national registries data from 2006 to 2022
thumbnail
Congress Presentation
Lipoprotein A and the risk of developing left ventricle systolic dysfunction in the immediate post-acute coronary syndrome period.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources